Evaluating the Impact of Variable Phosphorothioate Content in Tricyclo-DNA Antisense Oligonucleotides in a Duchenne Muscular Dystrophy Mouse Model
- 30 May 2019
- journal article
- research article
- Published by SAGE Publications in Nucleic Acid Therapeutics
- Vol. 29 (3) , 148-160
Abstract
Antisense oligonucleotides (ASOs) hold promise for therapeutic splice switching correction for genetic diseases, in particular for Duchenne muscular dystrophy (DMD), for which ASO-exon skipping represents one of the most advanced therapeutic strategies. We have previously reported the therapeutic potential of tricyclo-DNA (tcDNA) in mouse models of DMD, highlighting the unique pharmaceutical properties and unprecedented uptake in many tissues after systemic delivery, including the heart and central nervous system. TcDNA-ASOs demonstrate an encouraging safety profile and no particular class-related toxicity, however, when administered in high doses for several months, mild renal toxicity is observed secondary to predictable phosphorothioate (PS)-ASO accumulation in kidneys. In this study, we investigate the influence of the relative content of PS linkages in tcDNA-ASOs on exon skipping efficacy. Mdx mice were injected intravenously once weekly for 4 weeks with tcDNA carrying various amounts of PS linkages (0%, 25%, 33%, 50%, 67%, 83%, and 100%). The results indicate that levels of exon-23 skipping and dystrophin rescue increase with the number of PS linkages in most skeletal muscles except in the heart. As expected, plasma coagulation times are shortened with decreasing PS content, and tcDNA-protein binding in serum directly correlates with the number of PS linkages on the tcDNA backbone. Altogether, these data contribute in establishing the appropriate sulfur content within the tcDNA backbone for maximal efficacy and minimal toxicity of the oligonucleotide.Keywords
This publication has 35 references indexed in Scilit:
- Current and Emerging Therapies for Duchenne Muscular DystrophyCurrent Treatment Options in Neurology, 2018
- Exon-skipping advances for Duchenne muscular dystrophyHuman Molecular Genetics, 2018
- The Use of Tricyclo-DNA Oligomers for the Treatment of Genetic DisordersBiomedicines, 2017
- Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding IssuesNucleic Acid Therapeutics, 2017
- Phosphorothioates, Essential Components of Therapeutic OligonucleotidesNucleic Acid Therapeutics, 2014
- Phosphorothioate Oligonucleotides: Effectiveness and ToxicityCurrent Drug Targets, 2014
- RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic PlatformAnnual Review of Pharmacology and Toxicology, 2010
- Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independentNucleic Acids Research, 1995
- Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus.Proceedings of the National Academy of Sciences, 1987
- Oligodeoxynucleotide stability in subcellular extracts and culture mediaJournal of Biochemical and Biophysical Methods, 1986